866-997-4948(US-Canada Toll Free)

Dyskinesia - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 157 Pages

Dyskinesia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H1 2017, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 11, 6, 18 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Dyskinesia - Overview 8
Dyskinesia - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Dyskinesia - Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 21
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Dyskinesia - Companies Involved in Therapeutics Development 28
Adamas Pharmaceuticals Inc 28
Addex Therapeutics Ltd 28
Advicenne SA 29
Astraea Therapeutics LLC 29
Avanir Pharmaceuticals Inc 30
Bionomics Ltd 30
Catalyst Biosciences Inc 31
Catalyst Pharmaceuticals Inc 31
Cavion LLC 32
Clevexel Pharma SAS 32
EpiVax Inc 33
Heptares Therapeutics Ltd 33
Ipsen SA 34
Merz Pharma GmbH & Co KgaA 34
Neurim Pharmaceuticals Ltd 35
Neurocrine Biosciences Inc 35
Neurolixis Inc 36
Osmotica Pharmaceutical Corp 36
Phenomenome Discoveries Inc 37
Sage Therapeutics Inc 37
SciFluor Life Sciences LLC 38
SOM Biotech SL 38
Synchroneuron Inc 39
Teva Pharmaceutical Industries Ltd 39
Dyskinesia - Drug Profiles 40
(dextromethorphan + quinidine sulfate) - Drug Profile 40
A-2M13677 - Drug Profile 45
abobotulinumtoxinA - Drug Profile 46
acamprosate calcium SR - Drug Profile 50
amantadine hydrochloride ER - Drug Profile 52
amantadine hydrochloride ER - Drug Profile 61
AT-127 - Drug Profile 62
AT-326 - Drug Profile 63
AT-403 - Drug Profile 64
befiradol - Drug Profile 65
brexanolone - Drug Profile 67
CPP-115 - Drug Profile 76
CVXL-0107 - Drug Profile 81
CX-8998 - Drug Profile 82
cycloserine - Drug Profile 83
deutetrabenazine - Drug Profile 84
dipraglurant IR - Drug Profile 90
Drug for Dyskinesia - Drug Profile 95
Drug for Tardive Dyskinesia - Drug Profile 96
Drugs for Dyskinesia - Drug Profile 97
Gene Therapy to Inhibit TRH for Dyskinesia - Drug Profile 98
HTL-14242 - Drug Profile 99
incobotulinumtoxin A - Drug Profile 100
IRL-790 - Drug Profile 104
JM-010 - Drug Profile 105
MLR-1019 - Drug Profile 107
NBI-640756 - Drug Profile 108
Neu-120 - Drug Profile 109
Neu-240 - Drug Profile 110
NXN-413 - Drug Profile 111
NXN-613 - Drug Profile 112
onabotulinumtoxinA - Drug Profile 113
PEUN-3 - Drug Profile 114
PPI-1011 - Drug Profile 115
RNAi Gene Therapy to Inhibit NURR1 for Dyskinesia - Drug Profile 116
SAGE-217 - Drug Profile 117
SK-609 - Drug Profile 120
Small Molecule for Dyskinesia - Drug Profile 121
Small Molecule for Dyskinesia - Drug Profile 122
Small Molecules for Neurodegenerative Disease - Drug Profile 123
Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile 124
Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 125
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 126
Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 127
Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile 128
SOM-3355 - Drug Profile 129
TC-8831 - Drug Profile 130
tetrabenazine - Drug Profile 131
valbenazine tosylate - Drug Profile 132
Dyskinesia - Dormant Projects 139
Dyskinesia - Discontinued Products 141
Dyskinesia - Product Development Milestones 142
Featured News & Press Releases 142
Appendix 153
Methodology 153
Coverage 153
Secondary Research 153
Primary Research 153
Expert Panel Validation 153
Contact Us 153
Disclaimer 154

List of Tables
Number of Products under Development for Dyskinesia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Dyskinesia - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
Dyskinesia - Pipeline by Addex Therapeutics Ltd, H1 2017
Dyskinesia - Pipeline by Advicenne SA, H1 2017
Dyskinesia - Pipeline by Astraea Therapeutics LLC, H1 2017
Dyskinesia - Pipeline by Avanir Pharmaceuticals Inc, H1 2017
Dyskinesia - Pipeline by Bionomics Ltd, H1 2017
Dyskinesia - Pipeline by Catalyst Biosciences Inc, H1 2017
Dyskinesia - Pipeline by Catalyst Pharmaceuticals Inc, H1 2017
Dyskinesia - Pipeline by Cavion LLC, H1 2017
Dyskinesia - Pipeline by Clevexel Pharma SAS, H1 2017
Dyskinesia - Pipeline by EpiVax Inc, H1 2017
Dyskinesia - Pipeline by Heptares Therapeutics Ltd, H1 2017
Dyskinesia - Pipeline by Ipsen SA, H1 2017
Dyskinesia - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2017
Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017
Dyskinesia - Pipeline by Neurocrine Biosciences Inc, H1 2017
Dyskinesia - Pipeline by Neurolixis Inc, H1 2017
Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp, H1 2017
Dyskinesia - Pipeline by Phenomenome Discoveries Inc, H1 2017
Dyskinesia - Pipeline by Sage Therapeutics Inc, H1 2017
Dyskinesia - Pipeline by SciFluor Life Sciences LLC, H1 2017
Dyskinesia - Pipeline by SOM Biotech SL, H1 2017
Dyskinesia - Pipeline by Synchroneuron Inc, H1 2017
Dyskinesia - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Dyskinesia - Dormant Projects, H1 2017
Dyskinesia - Dormant Projects, H1 2017 (Contd..1), H1 2017
Dyskinesia - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Dyskinesia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *